Navigation Links
Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
Date:10/29/2009

the overall percent weight loss in the EQUIP study was 11% for patients on full dose Qnexa, as compared to 1.6% for the placebo group."

Also included in the presentation were discontinuation rates for cognitive events. Overall, these rates were low and the events were generally mild to moderate and reversible with discontinuation of treatment. There was one severe event in the treatment arm and one in the placebo arm that led to discontinuation. Specifically, the discontinuation rates for various cognitive-related events were as follows:


    % of Patients             EQUIP (n=1,264)           CONQUER (n=2,485)
    -------------       ------------------------    -------------------------
    MedDRA Preferred               Qnexa   Qnexa               Qnexa    Qnexa
     Terms              Placebo     Low     Full    Placebo     Mid     Full
    ----------------    -------    -----   -----    -------    -----    -----
    Disturbance in
     Attention             0.4%     0.0%     1.4%      0.1%     0.0%     0.7%
    Memory Impairment      0.0%     0.0%     0.0%      0.1%     0.0%     0.5%
    Amnesia
     (forgetfulness)       0.2%     0.0%     0.6%      0.0%     0.2%     0.3%
    Aphasia (word
     finding
     difficulties)         0.0%     0.0%     0.2%      0.0%     0.0%     0.3%
    Cognitive Disorder     0.2%     0.0%     0.0%      0.0%     0.0%     0.2%
    Confusional State      0.0%     0.4%     0.2%      0.1%     0.2%     0.1%
    Bradyphrenia
     (slow thinking)       0.0%     0.0%     0.2%      0.0%     0.0%     0.0%
    Disorientation         0.0%     0.0%     0.0%      0.0%     0.0%     0.0%
    Mental Impairment      0.0%     0.0%     0.0%      0.0%     0.0%     0.0%

    Events are not additive as some patients have reported more than one event
    leading to study drug discontinuation.

Consistent with standard scientific and regulatory methodologies, these infrequent events that lead to study drug discontinuati
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
10. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
11. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... The Temple Health & Bioscience District (THBD) today ... at 1802 South First St. in the Temple Medical and ... City of Temple to receive funding for ... Texas Veterans Health Care System, the new facility will enable ... biotechnology and life science companies. ...
(Date:3/27/2015)... , March 27, 2015   Cypher Genomics, ... announced new data showing that, compared to a ... technology provided highly equivalent interpretations of whether certain ... did so in a fraction of the time. ... for more comprehensive genetic analysis in non-invasive prenatal ...
(Date:3/27/2015)... March 27, 2015 A new report from Kalorama ... – Chile , ... top targets for IVD firms.  The healthcare research firm said ... IVD strategies for the Latin American continent with a population ... distributed supply operations. However, the country,s regional economic clout does ...
Breaking Medicine Technology:Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4
(Date:3/27/2015)... Ticket Down is a reputable source for authentic tickets for ... phenomenal and highly successful live tour last year, the cast of ... again in 2015 and they will be visiting 8 cities along ... New York City at the cozy Beacon Theatre and will wrap ... , Fans of the hit show can look forward to seeing ...
(Date:3/27/2015)... Dallas, TX (PRWEB) March 27, 2015 ... Landscape – Germany” is an essential source of ... and reimbursement landscape in Germany. Germany’s increasingly elderly ... drivers of its pharmaceutical market. In 2013, the ... expected to increase at Compound Annual Growth Rate ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 While deep learning ... 2015 GPU technology conference (GTC) , the CEO of one ... and push the human lifespan well beyond the generally-agreed ceiling ... informatics company , is one of 12 companies recognized as ... other startups in the GTC Emerging Companies Summit ...
(Date:3/27/2015)... NE (PRWEB) March 27, 2015 Ticket Down ... at the CenturyLink Center in Omaha, Nebraska on Friday, ... possibility that more concert dates will be added in Omaha ... of fan demand. , The Garth Brooks World Tour is ... the latest announcement that Garth Brooks and Trisha Yearwood will ...
(Date:3/27/2015)... According to a recently published report series by ... market in Europe is in decline due to decreasing ... Price decreases are being seen across the entire orthopedic ... total European trauma device market, continued pricing pressure overall ... after year. , “Such price drops are typical ...
Breaking Medicine News(10 mins):Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3
... minor ... problem,- 57% are unaware that diaper rash can be accompanied by a doctor ... - 59% responded "no" or were unsure when asked if there was a connection ... between diaper rash and antibiotics, PRINCETON, N.J., June 17 Barrier,Therapeutics, Inc. (Nasdaq: ...
... 17 Gentiva Health,Services, Inc. (Nasdaq: GTIV ), ... today that it is scheduled to,present from 1:00 to ... Jefferies,2nd Annual Healthcare Conference in New York., The ... live audio web,cast, which may be accessed by visiting, ...
... bullet, to help miilions of children in developing ... -- A new compound that may lead to an ... researchers at the University of Texas Health Science Center ... important for developing countries, where diarrhea is a major ...
... UK and Philadelphia, US June 17, 2008 ... biopharmaceutical company, today announced the publication of data from ... of ulcerative colitis (UC) drug Lialda™ (mesalamine). The primary ... and tolerability of Lialda in mild-to-moderate UC patients over ...
... CHICAGO, June 17 U.S. Environmental,Protection Agency Region 5 this ... hazards from underground soil contamination in,St. Louis Park, Minn., ... and,businesses are scheduled for July 10, 2 to 4 p.m. ... High School cafeteria, 6425 W. 33rd St. EPA,s,storefront office at ...
... be released at AHIP Institute July 18-20, ... from,URAC provides answers for health plans and health ... new trends in outsourcing of,credentialing services., (Logo: ... become available during the AHIP Institute, June 18-20,in ...
Cached Medicine News:Health News:Vusion Baby Bottom Line Report: Many Moms Don't Know that Their Babies' Irritated Skin Could Indicate a Severe Diaper Rash that Requires Medical Treatment 2Health News:Vusion Baby Bottom Line Report: Many Moms Don't Know that Their Babies' Irritated Skin Could Indicate a Severe Diaper Rash that Requires Medical Treatment 3Health News:Vusion Baby Bottom Line Report: Many Moms Don't Know that Their Babies' Irritated Skin Could Indicate a Severe Diaper Rash that Requires Medical Treatment 4Health News:Gentiva(R) Health Services to Present June 24 at Jefferies' 2nd Annual Healthcare Conference in New York 2Health News:Gentiva(R) Health Services to Present June 24 at Jefferies' 2nd Annual Healthcare Conference in New York 3Health News:Inexpensive Compound Could Treat Severe Diarrhea 2Health News:Long-term safety data on Lialda published in leading GI journal 2Health News:Long-term safety data on Lialda published in leading GI journal 3Health News:St. Louis Park Vapor Systems Installation Nearly Complete; Meeting July 10 2Health News:New URAC Issue Brief Answers Questions About Delegated Credentialing, Transparency in Physician Tiering Programs 2Health News:New URAC Issue Brief Answers Questions About Delegated Credentialing, Transparency in Physician Tiering Programs 3
... Acid powder reagent once reconstituted offers the ... stability to help maximize laboratory productivity, minimize ... time. The proprietary technology of the Infinity ... shelf life and stability once reconstituted that ...
... Glucose Oxidase single liquid stable reagent ... of single liquid stability to help ... and provide quick result turnaround time. ... Glucose Oxidase reagent provides a long ...
... reagent is intended for the in ... serum. , Infinity Cholesterol powder reagent ... stability once reconstituted and convenience, but ... existing assays. The reagent is suitable ...
...
Medicine Products: